➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Mallinckrodt
Merck
Dow
Harvard Business School

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Methoxyamine


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Methoxyamine?

Methoxyamine is an investigational drug.

There have been 6 clinical trials for Methoxyamine. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Lymphoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are National Cancer Institute (NCI), Case Comprehensive Cancer Center, and [disabled in preview].

There are three US patents protecting this investigational drug and thirty-six international patents.

Recent Clinical Trials for Methoxyamine
TitleSponsorPhase
Methoxyamine and Temozolomide in Treating Patients With Recurrent GlioblastomaNational Cancer Institute (NCI)Phase 2
Methoxyamine, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 1
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and PemetrexedNational Cancer Institute (NCI)Phase 1/Phase 2

See all Methoxyamine clinical trials

Clinical Trial Summary for Methoxyamine

Top disease conditions for Methoxyamine
Top clinical trial sponsors for Methoxyamine

See all Methoxyamine clinical trials

US Patents for Methoxyamine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Methoxyamine   Start Trial 4-substituted pyrazolo[3,4-d]pyrimidine derivatives Ortho Pharmaceutical Corporation (Raritan, NJ)   Start Trial
Methoxyamine   Start Trial Macrolide compounds American Cyanamid Company (Stamford, CT)   Start Trial
Methoxyamine   Start Trial Benzo[1,8]naphthyridine derivatives, their preparation and the compositions which contain them Laboratoire Roger Bellon (Seine, FR)   Start Trial
Methoxyamine   Start Trial Inosose derivatives, production and use thereof Takeda Chemical Industries, Ltd. (Osaka, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Methoxyamine

Drugname Country Document Number Estimated Expiration Related US Patent
Methoxyamine Australia 3088389 2008-03-03   Start Trial
Methoxyamine Australia 612797 2008-03-03   Start Trial
Methoxyamine China 1030605 2008-03-03   Start Trial
Methoxyamine China 1036766 2008-03-03   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Merck
Moodys
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.